JP2017517538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517538A5 JP2017517538A5 JP2016572302A JP2016572302A JP2017517538A5 JP 2017517538 A5 JP2017517538 A5 JP 2017517538A5 JP 2016572302 A JP2016572302 A JP 2016572302A JP 2016572302 A JP2016572302 A JP 2016572302A JP 2017517538 A5 JP2017517538 A5 JP 2017517538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- ring
- pyridazin
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- MPNAKLGQWGUYOO-UHFFFAOYSA-N 3-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]-5-fluoro-N-methylbenzamide Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC(=CC(=C1)F)C(=O)NC)F MPNAKLGQWGUYOO-UHFFFAOYSA-N 0.000 claims 1
- JMXQSRJJPVLGLQ-UHFFFAOYSA-N 3-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]benzamide Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC(=CC=C1)C(=O)N)F JMXQSRJJPVLGLQ-UHFFFAOYSA-N 0.000 claims 1
- ZBZGITBHHLRNSX-UHFFFAOYSA-N 5-[2-fluoro-5-(7-propan-2-ylimidazo[4,5-c]pyridazin-4-yl)phenyl]-2-methyl-3H-isoindol-1-one Chemical compound FC1=C(C=C(C=C1)C=1C2=C(N=NC=1)N(C=N2)C(C)C)C=1C=C2CN(C(C2=CC=1)=O)C ZBZGITBHHLRNSX-UHFFFAOYSA-N 0.000 claims 1
- AZSCZGPLVZULKG-UHFFFAOYSA-N 5-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]-2-methyl-3H-isoindol-1-one Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C=1C=C2CN(C(C2=CC=1)=O)C)F AZSCZGPLVZULKG-UHFFFAOYSA-N 0.000 claims 1
- XPSAGIQSESMIJK-UHFFFAOYSA-N 5-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]-6-methoxy-2-methyl-3H-isoindol-1-one Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C=1C=C2CN(C(C2=CC=1OC)=O)C)F XPSAGIQSESMIJK-UHFFFAOYSA-N 0.000 claims 1
- CHIRBXJNJJPPBZ-UHFFFAOYSA-N 6-[5-(7-ethylimidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]-2-methyl-3H-isoindol-1-one Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC=C2CN(C(C2=C1)=O)C)F CHIRBXJNJJPPBZ-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011137P | 2014-06-12 | 2014-06-12 | |
| US62/011,137 | 2014-06-12 | ||
| PCT/IB2015/054200 WO2015189744A1 (en) | 2014-06-12 | 2015-06-03 | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017517538A JP2017517538A (ja) | 2017-06-29 |
| JP2017517538A5 true JP2017517538A5 (enExample) | 2018-07-12 |
| JP6491679B2 JP6491679B2 (ja) | 2019-03-27 |
Family
ID=53434408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572302A Active JP6491679B2 (ja) | 2014-06-12 | 2015-06-03 | Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9802945B2 (enExample) |
| EP (1) | EP3154979B1 (enExample) |
| JP (1) | JP6491679B2 (enExample) |
| CA (1) | CA2951497C (enExample) |
| ES (1) | ES2664810T3 (enExample) |
| WO (1) | WO2015189744A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180031721A (ko) | 2015-07-17 | 2018-03-28 | 오비드 테라퓨틱스 인크. | 가복사돌로 발달장애들을 치료하는 방법들 |
| JP2018536677A (ja) * | 2015-12-10 | 2018-12-13 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | てんかんおよび疼痛の治療において使用するための、ＧＡＢＡ受容体モジュレーターとしての式（Ｉ）の４−（ビフェン−３−イル）−１Ｈ−ピラゾロ［３，４−ｃ］ピリダジン誘導体 |
| EP3476881B1 (en) * | 2016-06-28 | 2021-12-01 | Toray Industries, Inc. | Epoxy resin composition, prepreg, and fiber-reinforced composite material |
| WO2018031748A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| US10813918B2 (en) | 2017-08-04 | 2020-10-27 | Ovid Therapeutics Inc. | Use of Gaboxadol in the treatment of diabetes and related conditions |
| EP3982937A4 (en) * | 2019-07-15 | 2022-08-10 | Ovid Therapeutics Inc. | PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT |
| EP4049661A4 (en) * | 2019-10-21 | 2023-11-08 | SK Biopharmaceuticals Co., Ltd. | USE OF AN IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND TO PREVENT, RELIEF OR TREAT DEVELOPMENTAL DISABILITIES |
| BR112022007522A2 (pt) * | 2019-10-22 | 2022-07-12 | Neurocycle Therapeutics Inc | Compostos moduladores alostéricos positivos de gabaa, métodos de produção e de usos dos mesmos |
| JP7774558B2 (ja) * | 2019-10-23 | 2025-11-21 | ニューロサイクル・セラピューティクス・インコーポレイテッド | Ｇａｂａａ受容体モジュレーターによるてんかん状態の治療 |
| CN120865250A (zh) * | 2022-02-25 | 2025-10-31 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
| CN117003756A (zh) * | 2022-05-04 | 2023-11-07 | 华东师范大学 | 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂 |
| CN117069725A (zh) | 2022-05-10 | 2023-11-17 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
| GB9921150D0 (en) | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
| ATE310740T1 (de) | 2000-11-10 | 2005-12-15 | Merck Sharp & Dohme | Imidazotriazin-derivate als liganden für gaba- rezeptoren |
| GB0117277D0 (en) | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006078891A2 (en) * | 2005-01-21 | 2006-07-27 | Neurogen Corporation | Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives |
| CL2008000835A1 (es) | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
| CU24099B1 (es) | 2009-01-12 | 2015-06-30 | Pfizer Ltd | Derivados de sulfonamida para el tratamiento del dolor |
| KR20120034639A (ko) | 2009-05-07 | 2012-04-12 | 아스트라제네카 아베 | 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750 |
| UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
-
2015
- 2015-06-03 ES ES15730284.5T patent/ES2664810T3/es active Active
- 2015-06-03 CA CA2951497A patent/CA2951497C/en not_active Expired - Fee Related
- 2015-06-03 US US15/316,552 patent/US9802945B2/en active Active
- 2015-06-03 WO PCT/IB2015/054200 patent/WO2015189744A1/en not_active Ceased
- 2015-06-03 EP EP15730284.5A patent/EP3154979B1/en not_active Not-in-force
- 2015-06-03 JP JP2016572302A patent/JP6491679B2/ja active Active